Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE

(ABBV)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Sales forecast by analysts have been recently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at USD 91.12.
  • Technically, the stock approaches a strong medium-term resistance at USD 89.02.
  • The company is in debt and has limited leeway for investment
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • The company's enterprise value to sales, at 4.79 times its current sales, is high.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ABBVIE-5.65%128 628
JOHNSON & JOHNSON8.78%369 462
ROCHE HOLDING AG25.45%263 079
MERCK AND COMPANY16.28%226 211
PFIZER-12.28%211 902
NOVARTIS22.87%208 547
BRISTOL-MYERS SQUIBB COMPAN..15.33%140 534
AMGEN20.09%138 902
NOVO NORDISK AS28.89%133 610
ASTRAZENECA23.58%124 877
SANOFI10.44%115 690
ELI LILLY AND COMPANY3.39%114 870
GLAXOSMITHKLINE15.97%112 257
BAYER AG14.23%75 098
TAKEDA PHARMACEUTICAL COMPA..21.13%62 841
ALLERGAN PLC39.44%61 181
More Results
Financials (USD)
Sales 2019 33 293 M
EBIT 2019 15 768 M
Net income 2019 8 578 M
Debt 2019 30 704 M
Yield 2019 4,94%
P/E ratio 2019 14,6x
P/E ratio 2020 10,1x
EV / Sales2019 4,79x
EV / Sales2020 4,05x
Capitalization 129 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes